BCLI Brainstorm Cell Therapeutics, Inc.
6,318
$0.457
$0.089
(24.18%)
| Watchers | 6,318 |
| 52-Wk Low | $0.134 |
| 52-Wk High | $3.34 |
| Market Cap | $25.56M |
| Volume | 1.04M |
| 52-Wk High | $3.34 |
| 52-Wk Low | $0.134 |
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwnPR Newswire • 22 days ago
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn BrainStorm Cell Therapeutics Announces Management Changes as Company Plans...
Share to Feed
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule PR Newswire NEW YORK, April...
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's Phase 3 Clinical Trial in ALS BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of...
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special...
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program BrainStorm Cell Therapeutics to Provide Update on NurOwn Program PR Newswire NEW YORK, April 8, 2024 A conference call and webcast...
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate...
Analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI Get Free Report) in a research note issued on Wednesday. The brokerage set a...
Stock analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI Get Free Report) in a research note issued to investors on Wednesday. The firm set a...
StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI Free Report) in a research report sent to investors on Monday morning. The firm issued a hold rating on...
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and...